Serious adverse events and fatal adverse events associated with nivolumab treatment in cancer patients: Nivolumab-related serious/fatal adverse events

BACKGROUND: Nivolumab, an immune checkpoint inhibitor, has revolutionized the treatment of many cancers. Due to its novel mechanisms of action, nivolumab induces a distinct profile of adverse events. Currently, the incidence and risk of developing serious adverse events (SAEs) or fatal adverse event...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhao, Bin, Zhao, Hong, Zhao, Jiaxin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6171173/
https://www.ncbi.nlm.nih.gov/pubmed/30285872
http://dx.doi.org/10.1186/s40425-018-0421-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6171173/
https://www.ncbi.nlm.nih.gov/pubmed/30285872
http://dx.doi.org/10.1186/s40425-018-0421-z

Ejemplares similares